research

Meta-analysis of clinical randomized controlled trials comparing ReZOOM with ReSTOR multifocal intraocular lenses in cataract surgery

Abstract

AIM: To systematic review the effectiveness of refractive multifocal intraocular lens(MIOL)ReZOOM <i>vs</i> diffractive MIOL ReSTOR in the treatment of cataract.<p>METHODS: Randomized controlled trials comparing refractive MIOL ReZOOM with diffractive MIOL ReSTOR were identified by searching CENTRAL, MEDLINE, EMbase, WANFANG MED ONLINE, CMJD, SinoMed, and CNKI. Related journals also were hand-searched. Methodological quality of randomized controlled trials(RCTs)was evaluated by simple evaluate method that recommended by the Cochrane Collaboration. Data extracted by two reviewers with designed extraction form. RevMan software(release 5.2)was used for data management and analysis.<p>RESULTS:A total of 7 trials(846 eyes)were included for systematic review. Subgroup analyses were used according to different model comparison of ReSTOR MIOL. The results showed a significant difference in the mean of the best distance corrected intermediate visual acuity(BDCIVA)in the ReZOOM MIOL group with WMD= -0.11, 95% <i>CI</i>(-0.16, -0.06)(<i>P</i><0.0001). It showed a significantly difference in the mean of the uncorrected near visual acuity(UCNVA), complete spectacle independent rate, halo rate and glare rate in the ReSTOR MIOL group with WMD= 0.09, 95% <i>CI</i>(0.05, 0.14)(<i>P</i><0.00001), WMD= 2.62, 95%<i>CI</i>(1.76, 3.91)(<i>P</i><0.00001), WMD=1.35, 95% <i>CI</i>(1.15, 1.60)(<i>P</i>=0.0004)and WMD= 1.29, 95% <i>CI</i>(1.09, 1.53)(<i>P</i>=0.003). There was no significant difference between the two groups in the mean of the uncorrected distance visual acuity(UCDVA), the uncorrected intermediate visual acuity(UCIVA), the best corrected distance visual acuity(BCDVA)and the best distance corrected near visual acuity(BDCNVA)with WMD -0.03, 95% <i>CI</i>(-0.06, 0.01)(<i>P</i>=0.15), WMD= -0.04, 95% <i>CI</i>(-0.09, 0.01)(<i>P</i>=0.10), WMD= -0.01, 95%<i>CI</i>(-0.04, 0.02)(<i>P</i>=0.55)and WMD= 0.06, 95% <i>CI</i>(-0.06, 0.17)(<i>P</i>=0.32). <p>CONCLUSION: Patients implanted with ReZOOM MIOL can provide better BDCIVA; patients implanted with ReSTOR MIOL show better UCNVA, are less likely to appear light halo, glare and other visual adverse reactions; correction in spectacles cases, patients implanted with ReZOOM or ReSTOR MIOL have considerable performances in the far and near visual acuity

    Similar works